Enact Holdings Inc
NASDAQ: ACT
$34.59
+$0.20 (+0.6%)
Real Time Data Delayed 15 Min.
ACT Stock Chart and Intraday Price
ACT Stock Data
| Asset Type | Stock |
| Exchange | NASDAQ |
| Currency | USD |
| Country | USA |
| Sector | FINANCE |
| Industry | INSURANCE AGENTS, BROKERS & SERVICE |
| Address | 8325 SIX FORKS ROAD, RALEIGH, NC, US |
| Fiscal Year End | December |
| Latest Quarter | 12/31/2023 |
| Market Cap | 4,423.77M USD |
| Shares Outstanding | 159,703,000 |
ACT Articles
A new ETF that includes only U.S. firms operating in the legal cannabis market made its first appearance on Wednesday.
Published:
Last Updated:
Many investors are focused on getting the jump on the cannabis industry, but they aren’t alone. With this increased speculation, there is added risk that has to be considered.
Published:
The ETF universe includes a variety of funds that allow investors to share in the spoils of legal gambling, smoking (tobacco and marijuana), and beer and spirits consumption. Investing in sin can pay...
Published:
Last Updated:
With evolving societal and regulatory landscapes, the upside potential of cannabis as a new investment strategy has emerged. Investors can use a number of ETFs to invest in the future of cannabis.
Published:
Last Updated:
Allergan has issued a press release that confirms some of the rumors floating in the market that it has been approached by Pfizer.
Published:
S&P Capital IQ released a report regarding the performance of companies in terms of earnings and revenue.
Published:
American Airlines will be the newest addition to the S&P 500, taking the place of Allergan.
Published:
All indexes rebalance on a quarterly basis. 24/7 Wall St. screened a recent Jefferies report for the stocks that will see the most trading on Friday's rebalance.
Published:
Salix Pharmaceuticals and Valeant Pharmaceuticals have announced that they had entered into an agreement on their plan to merge based on a new price for Salix shares.
Published:
A new report from UBS shows some serious changes made to the firm's Equity Focus list for March.
Published:
Actavis launched second-largest ever bond sale Monday to raise $21 billion to pay for its acquisition of Allergan.
Published:
Last Updated:
The UBS CIO Wealth Management team makes a good case that investors should consider the stocks in the firm's Quality Growth at a Reasonable Price (Q-GARP) portfolio.
Published:
24/7 Wall St. has compiled a list health care stocks that Merrill Lynch expects to be top performers in 2015.
Published:
Last Updated:
Here is a look at the top performers for 2014, nine stocks that have doubled and have a current market cap of at least $5 billion.
Published:
Last Updated:
While this was generally a known event coming down the pipe, arthritis drug Celebrex now has a generic competitor in America.
Published: